Vyvanse Initial Dose
The recommended initial dose of Vyvanse (lisdexamfetamine) is 30 mg once daily in the morning for both adults and pediatric patients 6 years and older with ADHD. 1
Standard Dosing Protocol
The FDA-approved labeling is clear and unambiguous about starting dosage:
- Starting dose: 30 mg once daily taken in the morning with or without food
- Titration schedule: Increase in increments of 10 mg or 20 mg at approximately weekly intervals
- Target dose range: 30-70 mg once daily
- Maximum dose: 70 mg once daily 1
When to Consider Lower Starting Doses
A 20 mg starting dose is NOT part of the standard FDA-approved dosing for ADHD. The available strengths include 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsules, but the prescribing information consistently specifies 30 mg as the initial dose 1.
However, lower doses may be appropriate in specific circumstances:
Renal Impairment Adjustments
- Severe renal impairment (GFR 15-29 mL/min/1.73 m²): Maximum dose should not exceed 50 mg daily
- End-stage renal disease (GFR <15 mL/min/1.73 m²): Maximum recommended dose is 30 mg daily 1
Preschool Children (Ages 4-5 Years)
Recent evidence suggests that in preschool-aged children, doses as low as 5-10 mg have been studied, though this remains off-label use 2. The effect sizes in this younger population appear smaller than in older children, and careful monitoring is essential.
Administration Details
Key administration points:
- Swallow capsules whole OR open and mix entire contents with yogurt, water, or orange juice (consume immediately, do not store)
- Chewable tablets must be chewed thoroughly before swallowing
- Avoid afternoon doses due to insomnia risk
- Do not divide a single dose—take at least one full capsule or tablet per day 1
Clinical Context
While older stimulant guidelines suggest starting with lower doses (e.g., 2.5 mg for dextroamphetamine/amphetamine products) 3, Vyvanse's prodrug design and extended-release properties justify the higher 30 mg starting dose. The medication requires enzymatic conversion to active dextroamphetamine, resulting in a smoother pharmacokinetic profile with lower abuse potential compared to immediate-release formulations 4, 5, 6.
Monitoring Requirements
Before initiating treatment, assess:
- Cardiac status: Perform careful history, family history of sudden death or ventricular arrhythmia, and physical examination
- Tics/Tourette's: Evaluate family history and clinically assess for motor or verbal tics 1
During titration (weekly intervals):
- Monitor ADHD symptoms using standardized rating scales
- Assess treatment-emergent adverse effects (decreased appetite, insomnia, irritability most common)
- Check blood pressure and pulse
- Monitor growth parameters in pediatric patients 1, 6
The 30 mg starting dose provides an appropriate balance between efficacy and tolerability, with systematic weekly titration allowing optimization based on individual response.